HEMF On Other Exchanges
Symbol
Exchange
Stockholm
Berlin
Stockholm
OTC US

hemfosa fastigheter ab (HEMF) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for HEMFOSA FASTIGHETER AB (HEMF)
\

Related News

No related news articles were found.

hemfosa fastigheter ab (HEMF) Related Businessweek News

No Related Businessweek News Found

hemfosa fastigheter ab (HEMF) Details

Hemfosa Fastigheter AB (publ) owns, acquires, develops, manages, and sells properties in Sweden, Norway, and Finland. Its property portfolio comprises community service properties, such as public authorities and judicial institutions, healthcare providers and retirement homes, schools, preschools, and office premises in municipalities. The company was founded in 2009 and is headquartered in Nacka, Sweden.

71 Employees
Last Reported Date: 04/12/19
Founded in 2009

hemfosa fastigheter ab (HEMF) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: kr5.9M
Compensation as of Fiscal Year 2018.
hemfosa fastigheter ab
Hemfosa Fastigheter AB (publ) Announces Ulrika Valassi Not Stand for Re-Election to the Board

Hemfosa Fastigheter AB (publ) has announced that Ulrika Valassi has declined re-election for board in the annual general meeting 2019.

Hemfosa Fastigheter AB (Publ) Proposes Dividend for Ordinary Shares and Preference Shares for the Year 2018

Hemfosa Fastigheter AB (publ) announced that for the 2018 fiscal year, the Board proposes that the AGM resolve to pay a dividend to ordinary shareholders of SEK 2.40 per ordinary share with quarterly payment of SEK 0.60 per share, as well as a dividend to preference shareholders of SEK 10.00 per preference share with quarterly payment of SEK 2.50 per share.

Hemfosa Fastigheter AB Publ Reports Earnings Results for the Fourth Quarter Ended December 31, 2018

Hemfosa Fastigheter AB publ announced earnings results for the fourth quarter ended December 31, 2018. For the fourth quarter, the company announced net loss was SEK 530 million compared to net income of SEK 527 million a year ago. Basic loss per share was SEK 3.28 compared to basic earnings per share of SEK 3.17 a year ago. Diluted loss per share was SEK 3.28 compared to diluted earnings per share of SEK 3.16 a year ago. For the full year, net income was SEK 2,327 million compared to SEK 3,142 million a year ago. Basic earnings per share was SEK 14.02 compared to SEK 19.22 a year ago. Diluted earnings per share was SEK 14.01 compared to SEK 19.21 a year ago.

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

HEMF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for HEMF.
View Industry Companies
 

Industry Analysis

HEMF

Industry Average

Valuation HEMF Industry Range
Price/Earnings 6.7x
Price/Sales 6.0x
Price/Book 1.3x
Price/Cash Flow 7.3x
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact HEMFOSA FASTIGHETER AB, please visit hemfosa.se. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.